Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Running, not enrolling · Not applicable

Conditions studied: Cervical Carcinoma, Human Papillomavirus Infection

In brief

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. HPV is known to cause a variety of cancers including cervical cancer. Even though there are ways to detect cervical cancer, many individuals are not diagnosed. Over half of all new cervical cancer cases are among those who have either never been screened or who are not screened enough. The low screening numbers show more testing needs to be done. Without appropriate screening and care, preventable precancer may turn into cancer. A new way to detect cervical cancer is to have individuals collect their own sample for HPV testing to know their risk for cervical cancer. This may give individuals more flexibility and comfort having the ability to collect samples themselves, compared to a doctor performing a speculum examination and collecting the samples in a clinic. Information gathered from this study compares clinical accuracy of HPV testing on self-collected vaginal samples versus cervical samples collected by clinician. The Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial is part of the National Cancer Institute (NCI)'s Cervical Cancer 'Last Mile' Initiative, a public private partnership that seeks to increase access to cervical cancer screening. The SHIP Trial focuses on developing clinical evidence to inform the US Food and Drug Administration (FDA)'s regulatory reviews of self-collection approaches as alternative sample collection approaches for cervical cancer screening. Several industry partner-specific self-collection device and assay combinations will be non-competitively and independently evaluated with a similar study design framework to inform pre-approval and/or post-approval regulatory requirements.

Key facts

Study ID

NCT06611540

Run by

National Cancer Institute (NCI)

People needed

500

Starts

2024-09-11

Expected to finish

2027-06-30

Last updated by the study team

2026-07-07

Who can join

Age: 25 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Willingness and ability to provide a documented informed consent.
• Is 25 years or older.
• Has an intact cervix.
• Has had a referral for colposcopy and/or cervical excisional procedure in which routine cervical cancer screening has included HPV testing (HPV primary screening, co-testing, or atypical squamous cells of undetermined significance [ASC-US] cytology triage) or abnormal cytology performed within the past 12 months preceding the referral visit.
• Willing and able to undergo colposcopy, and if clinically indicated for SOC purposes, a biopsy, endocervical curettage, and/or a cervical excisional procedure, as applicable.

You may not qualify if…

• Is pregnant when presenting for the referral visit or gave birth within the past 3 months.
• Has a known history of excisional or ablative therapy to the cervix (e.g., loop electrosurgical excision procedure [LEEP], cone biopsy, cervical laser surgery, cryotherapy, thermal ablation) in the last 12 months prior to the referral visit.
• Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records.
• Known medical conditions that, in the opinion of the investigator, preclude study participation.
• Previous participation in the SHIP Trial. Participation is defined as completing the self-collection.
• Is experiencing unusual bleeding or pelvic pain.

Where it is running

• Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States
• UofL Health Medical Center Northeast — Louisville, Kentucky, United States
• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
• Minneapolis VA Medical Center — Minneapolis, Minnesota, United States
• University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Montefiore Medical Center-Einstein Campus — The Bronx, New York, United States
• UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States
• University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio, United States
• University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania, United States
• UT MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.